

## RESEARCH MONOGRAPH . COMPOUND PROFILE

# Nafarelin

*A synthetic decapeptide analog of gonadotropin-releasing hormone bearing a D-3-(2-naphthyl)alanine substitution at position 6, developed at Syntex Research as an intranasal GnRH superagonist approximately 200-fold more potent than native GnRH, FDA-approved for endometriosis and central precocious puberty through sustained pituitary gonadotrope desensitization and consequent suppression of gonadal steroidogenesis.*

|                |                                                                                                               |
|----------------|---------------------------------------------------------------------------------------------------------------|
| DOCUMENT       | KDC-MN-1396                                                                                                   |
| ISSUED         | 2026-05-10                                                                                                    |
| REVISION       | 1.0                                                                                                           |
| AUTHOR         | Kodi <i>ac</i> bio <i>l</i> abs Research                                                                      |
| COMPOUND CLASS | Gonadotropin-releasing hormone superagonist decapeptide with pituitary GnRH receptor desensitization activity |

RESEARCH USE ONLY

## ABSTRACT

Nafarelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolyl-glycinamide; CAS 76932-56-4 free base; molecular formula C<sub>66</sub>H<sub>83</sub>N<sub>17</sub>O<sub>13</sub>; molecular weight 1322.47) is a synthetic decapeptide superagonist analog of gonadotropin-releasing hormone (GnRH) that achieves approximately 200-fold greater receptor affinity than the native decapeptide through substitution of the bulky hydrophobic D-3-(2-naphthyl)alanine residue at position 6, conferring both enhanced receptor binding and resistance to aminopeptidase degradation. Developed at Syntex Research in the early 1980s and approved by the United States Food and Drug Administration on February 13, 1990 as Synarel (nafarelin acetate nasal solution), the compound was the first new pharmacotherapy for endometriosis to enter the US market in 14 years and remains the only GnRH agonist administered exclusively by intranasal spray in clinical practice. The mechanism of action follows the class pharmacology of GnRH superagonists: acute administration produces an initial stimulatory flare of luteinizing hormone and follicle-stimulating hormone release from anterior pituitary gonadotropes, followed within 2 to 4 weeks of continuous twice-daily intranasal dosing by profound receptor desensitization, downregulation of GnRH receptor expression, and consequent suppression of gonadotropin secretion to castrate or prepubertal levels, with parallel suppression of ovarian estradiol to postmenopausal concentrations (less than 20 pg/mL) or testicular testosterone to castrate concentrations. The resulting pharmacological hypoestrogenism or hypogonadism underlies the established

clinical applications: management of pelvic pain and reduction in size and number of endometriotic implants in women 18 years and older (400 micrograms daily by intranasal spray for 6 months), and suppression of pubertal development in children with central precocious puberty (1600 micrograms daily by intranasal spray). An additional established clinical application is pituitary downregulation prior to controlled ovarian hyperstimulation in assisted reproductive technology cycles, where nafarelin produces pituitary suppression equivalent to leuprolide and triptorelin with the operational advantage of non-injectable self-administration. Pharmacokinetics after intranasal administration are characterized by rapid absorption through the nasal mucosa (peak plasma concentration at 10 to 40 minutes), low absolute bioavailability of approximately 2.8 percent (range 1.2 to 5.6 percent), plasma protein binding of 80 percent, metabolism by tissue peptidases rather than hepatic cytochrome P450 enzymes, and an elimination half-life of 2.5 to 3.0 hours by the intranasal route. The compound is well tolerated within the constraints of its mechanism: the principal adverse events are the predictable consequences of pharmacological hypoestrogenism (hot flashes in up to 90 percent of adult patients, decreased bone mineral density of 3 to 6 percent over 6 months of treatment with partial but incomplete reversal on cessation, vaginal dryness, decreased libido, emotional lability) and local nasal irritation (approximately 10 percent). The bone mineral density concern limits treatment duration to 6 months in the registered endometriosis indication without add-back therapy. This monograph reviews the chemistry, synthesis, and structure-activity relationships of nafarelin; the GnRH receptor pharmacology and desensitization mechanism; comprehensive pharmacokinetics; the clinical evidence base across endometriosis, central precocious puberty,

assisted reproduction, uterine leiomyomas, and investigational applications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse-event profile; and a comparative assessment of five GnRH agonist alternatives against nafarelin on five competency standards.

# 1. Compound Identification

## 1.1 Names, synonyms, and registry identifiers

**International Nonproprietary Name:** Nafarelin.

**Marketed names:** Synarel (Syntex, subsequently Roche, subsequently Pfizer; United States, United Kingdom, Australia, New Zealand, Canada, several European Union member states, Japan).

**Development codes:** RS-94991-298 (Syntex Research). The development code appears in the early pharmacology and structure-activity relationship literature from the Syntex peptide chemistry group [1].

**Chemical Abstracts Service registry numbers:** 76932-56-4 (free base), 86220-42-0 (acetate salt). The acetate salt is the formulated pharmaceutical form; the free base is the synthetic and reference standard form.

**International Union of Pure and Applied Chemistry name:** 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolyl-glycinamide. The compound is a decapeptide analog of the hypothalamic gonadotropin-releasing hormone (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH<sub>2</sub>), with substitution of D-3-(2-naphthyl)alanine for glycine at position 6.

## 1.2 Structural class and chemistry

Nafarelin is a synthetic decapeptide belonging to the gonadotropin-releasing hormone superagonist class. The structural class comprises analogs of native GnRH in which the glycine at position 6 is replaced by a D-amino acid (conferring resistance to endopeptidase cleavage at the Tyr<sup>5</sup>-Gly<sup>6</sup> bond and enhancing receptor affinity through hydrophobic interactions at the receptor binding pocket) [2]. Nafarelin is distinguished within this class by the use of D-3-(2-naphthyl)alanine (D-Nal(2)) at position 6, a large bicyclic aromatic residue that provides the highest receptor affinity among the clinically developed position-6 substitutions and approximately 200-fold greater potency than native GnRH in pituitary gonadotropin release assays [3].

**Molecular formula:** C<sub>66</sub>H<sub>83</sub>N<sub>17</sub>O<sub>13</sub> (free base); C<sub>68</sub>H<sub>87</sub>N<sub>17</sub>O<sub>15</sub> (acetate salt, anhydrous).

**Exact mass:** 1321.6391 g/mol (free base, monoisotopic).

**Molecular weight:** 1322.47 g/mol (free base); 1382.52 g/mol (acetate salt, anhydrous).

**Physical properties:** White to off-white lyophilized powder. Freely soluble in water and in dilute acetic acid; soluble in methanol; sparingly soluble in apolar organic solvents. The compound is hygroscopic in lyophilized form and should be stored under desiccation. The acetate salt is the pharmaceutical form; conversion between free base and acetate salt masses requires accounting for the acetate counterion stoichiometry.

**Amino acid sequence:** pGlu-His-Trp-Ser-Tyr-D-Nal(2)-Leu-Arg-Pro-Gly-NH<sub>2</sub>. The C-terminus is amidated (glycinamide), consistent with the native GnRH structure. The single structural modification relative to native GnRH is at position 6: D-3-(2-naphthyl)alanine replaces glycine.

**Stereochemistry:** The compound contains 8 amino acid stereocenters in the L-configuration and one in the D-configuration (position 6). The D-configuration at position 6 is essential for biological activity; the L-Nal(2)<sub>6</sub> epimer has substantially reduced GnRH receptor affinity and is not pharmacologically active at relevant concentrations. Investigators should confirm peptide stereochemical integrity by chiral amino acid analysis or by functional bioassay.

## 1.3 Synthesis

The synthesis of nafarelin follows standard solid-phase peptide synthesis methodology. The decapeptide is assembled sequentially on a solid support (typically Wang resin or Rink amide resin for the C-terminal glycinamide) using fluorenylmethyloxycarbonyl (Fmoc) or tert-butyloxycarbonyl (Boc) protection strategies [4]. The D-3-(2-naphthyl)alanine at position 6 is incorporated as the Fmoc-D-Nal(2)-OH or Boc-D-Nal(2)-OH building block during the coupling cycle. Side-chain protecting groups for histidine (trityl), tryptophan (Boc), serine (tert-butyl), tyrosine (tert-butyl), and arginine (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl) are standard. The N-terminal pyroglutamyl residue is introduced either directly as Fmoc-pGlu-OH or by on-resin cyclization of glutamine after final deprotection. Cleavage from resin and global deprotection is accomplished with trifluoroacetic acid cocktails. Purification is by preparative reversed-phase high-performance liquid chromatography. The acetate salt is formed by lyophilization from dilute acetic acid. Pharmaceutical-grade

nafarelin acetate is manufactured to greater than 98 percent purity by HPLC with full characterization by amino acid analysis, mass spectrometry, and peptide content determination [5].

## 2. Abstract

Nafarelin (Synarel; RS-94991-298) is a synthetic decapeptide gonadotropin-releasing hormone superagonist with approximately 200-fold greater potency than native GnRH at the pituitary GnRH receptor, developed at Syntex Research and approved by the United States Food and Drug Administration in February 1990 for the management of endometriosis-associated pelvic pain [6]. The compound was subsequently approved for central precocious puberty in 1993 and is used off-label for pituitary downregulation in assisted reproductive technology protocols and as preoperative treatment for uterine leiomyomas.

The mechanism of action follows the paradoxical pharmacology of GnRH superagonists: initial agonist stimulation of pituitary gonadotropes produces a transient flare of luteinizing hormone and follicle-stimulating hormone release (lasting 1 to 2 weeks), followed by sustained receptor desensitization through receptor internalization, uncoupling from Gq/11 signaling, and downregulation of GnRH receptor messenger RNA transcription [7, 8]. The consequence is a reversible medical castration: gonadal steroid output falls to postmenopausal or prepubertal levels within 2 to 4 weeks of continuous administration, producing the therapeutic estrogen-deprivation state that underlies all registered and investigational indications.

The pivotal Henzl et al. (1988) randomized double-blind trial in the New England Journal of Medicine demonstrated that nafarelin 400 micrograms daily by intranasal spray for 6 months produced statistically significant reductions in American Fertility Society laparoscopic endometriosis scores (from 21.9 to 12.6,  $P$  less than 0.0001) and in symptom severity (proportion with severe symptoms reduced from approximately 40 percent to 5 to 10 percent), with efficacy equivalent to the then-standard danazol 800 mg daily but with a substantially more favorable metabolic and androgenic adverse-event profile [9]. The European Nafarelin Endometriosis Trial (NEET,  $n=247$ ) subsequently confirmed these findings in a large-scale danazol-controlled multicenter study [10].

In central precocious puberty, nafarelin 1600 micrograms daily by intranasal spray produces sustained suppression of pubertal gonadotropin and sex steroid levels, arrest of secondary sexual development, and deceleration of skeletal matu-

ration, with documented reversal of all suppressive effects within one year of treatment discontinuation in 100 percent of children studied [11, 12].

Pharmacokinetics are characterized by rapid nasal mucosal absorption (peak concentration at 10 to 40 minutes), low bioavailability (2.8 percent), metabolism by tissue peptidases, and a terminal elimination half-life of 2.5 to 3.0 hours [13]. The low bioavailability is compensated by the high receptor potency, such that the delivered fraction is pharmacologically adequate for complete pituitary suppression at twice-daily dosing.

The compound is well tolerated within the pharmacological constraints of hypoestrogenism. Treatment duration in the endometriosis indication is limited to 6 months by the concern of progressive bone mineral density loss (3 to 6 percent vertebral bone loss over 6 months, with partial but incomplete recovery at 12 to 15 months post-treatment) [14, 15]. Add-back hormonal therapy with low-dose norethindrone acetate or tibolone mitigates bone loss and vasomotor symptoms without compromising efficacy, extending the feasible treatment duration.

## 3. Discovery and Development History

### 3.1 Origin

Nafarelin was synthesized at Syntex Research (Palo Alto, California) in the late 1970s as part of an extensive structure-activity relationship program on GnRH analogs directed by the Syntex peptide chemistry group [1, 3]. The program was stimulated by the discovery of Schally and colleagues that substitution of D-amino acids at position 6 of the native GnRH decapeptide produced superagonist analogs with enhanced receptor affinity and resistance to enzymatic degradation. The Syntex group systematically explored large hydrophobic D-amino acids at position 6 and identified the D-3-(2-naphthyl)alanine substitution as producing optimal receptor affinity, lipophilicity for nasal mucosal absorption, and biological potency in vivo [3].

### 3.2 Preclinical development

Preclinical characterization demonstrated that nafarelin was approximately 200-fold more potent than native GnRH in stimulating luteinizing hormone release from rat anterior pituitary cells in vitro and in suppressing ovarian function on chronic administration in rats and monkeys [16]. The compound was selected for clinical development on the basis of this potency advantage, its suitability for intranasal delivery (the naphthylalanine residue enhances lipophilicity and nasal mucosal partitioning), and its favorable preclinical toxicology profile. Syntex advanced nafarelin through Phase 1 pharmacokinetic studies by the intranasal route in the early 1980s and through Phase 2 and Phase 3 clinical trials for endometriosis in the mid-1980s.

### 3.3 Regulatory approval

The New Drug Application for Synarel (nafarelin acetate nasal solution, 2 mg/mL delivering 200 micrograms per spray actuation) was submitted to the FDA in November 1988. The Fertility and Maternal Health Drugs Advisory Committee recommended approval unanimously (9 to 0, with one abstention) in April 1989. Final FDA approval was granted on February 13, 1990 for the indication of management

of endometriosis including pain relief and reduction of endometriotic lesions in women 18 years and older [6]. The drug was rated a "1B" new molecular entity. Syntex stated at the time that the FDA was the first regulatory agency worldwide to approve the product. Approval for central precocious puberty followed in 1993.

### 3.4 Corporate succession

Syntex was acquired by Roche in 1994. The Synarel franchise was subsequently transferred to Pfizer through portfolio restructuring. The product remains marketed under the Synarel brand name and is available in the United States, United Kingdom, Australia, New Zealand, Canada, Japan, and multiple European Union member states. Generic nafarelin acetate nasal spray has been approved in some jurisdictions; the compound is off-patent.

### 3.5 Expansion of clinical applications

Following the endometriosis approval, nafarelin was studied and adopted for three additional clinical applications: central precocious puberty (FDA-approved 1993); pituitary downregulation in in vitro fertilization and assisted reproductive technology protocols (off-label but widely used from the early 1990s); and preoperative shrinkage of uterine leiomyomas prior to myomectomy or hysterectomy (off-label) [17, 18]. The compound has also been studied in prostate cancer, breast cancer adjuvant endocrine therapy, and premenstrual syndrome, though these applications have not produced registered indications.

## 4. Mechanism of Action

### 4.1 GnRH receptor pharmacology

The gonadotropin-releasing hormone receptor (GnRHR) is a seven-transmembrane G protein-coupled receptor expressed predominantly on anterior pituitary gonadotrope cells, with lower-level expression on some reproductive tissues, immune cells, and tumor cell lines [7]. The receptor is coupled to Gq/11 and signals principally through phospholipase C-beta activation, inositol trisphosphate generation, diacylglycerol production, and intracellular calcium mobilization. The downstream consequence of pulsatile GnRH stimulation is synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Nafarelin binds the GnRH receptor with approximately 200-fold greater affinity than native GnRH [3]. The enhanced affinity derives from two structural contributions: the D-configuration at position 6 eliminates the susceptibility to endopeptidase cleavage at the Tyr5-Gly6 bond and provides a conformational fit to the receptor binding pocket; the bulky 2-naphthyl aromatic system makes extensive hydrophobic contacts with the receptor transmembrane domains and extracellular loop regions that are not achieved by the native glycine side chain [2, 8].

### 4.2 Biphasic response: flare and desensitization

The pharmacological response to continuous nafarelin administration is biphasic [7, 8]:

**Phase 1 (stimulatory flare, days 1 to 14):** Initial binding to the GnRH receptor activates the Gq/11 signaling cascade and stimulates release of stored LH and FSH from gonadotrope secretory granules. Plasma LH and FSH rise transiently (the "flare"), with consequent transient elevation of gonadal steroids (estradiol in women, testosterone in men). In women with endometriosis, the estradiol flare may produce transient symptom exacerbation. In men with prostate cancer treated with GnRH agonists, the testosterone flare can produce transient disease progression (the rationale for androgen receptor antagonist flare coverage).

**Phase 2 (desensitization, days 14 to 28 and beyond):** Continuous receptor stimulation produces several molecular consequences: GnRH receptor internalization through beta-arrestin-mediated endocytosis; uncoupling of the receptor from Gq/11 through G-protein-coupled receptor kinase phosphorylation; downregulation of GnRH receptor mRNA transcription; depletion of intracellular calcium stores; and reduced synthesis of LH and FSH subunit mRNAs [7]. The composite effect is profound suppression of gonadotropin secretion, with LH and FSH falling to or below the lower limit of assay detection. The consequent loss of gonadotropin stimulation of the gonads produces estradiol suppression to postmenopausal levels (less than 20 pg/mL) in women and testosterone suppression to castrate levels (less than 50 ng/dL) in men.

## 4.3 Reversibility

The desensitization is fully reversible on cessation of nafarelin administration. Pituitary GnRH receptor expression recovers within 2 to 4 weeks of drug withdrawal, gonadotropin secretion resumes, and gonadal steroidogenesis returns to pretreatment levels [11, 12]. In women treated for endometriosis, menses typically resume within 4 to 8 weeks of treatment cessation. In children with central precocious puberty, pubertal gonadotropin levels, sex steroid levels, and secondary sexual development resume within one year of treatment cessation in all subjects studied.

## 4.4 Tissue-level consequences

The suppression of gonadal steroidogenesis produces estrogen-dependent tissue atrophy that underlies the therapeutic effects:

**Endometrium and endometriotic implants:** Estrogen deprivation produces endometrial atrophy and regression of ectopic endometrial implants. Laparoscopic scoring demonstrates reduction in implant size, number, and vascularity after 3 to 6 months of nafarelin-induced estrogen suppression [9, 10].

**Uterine leiomyomas:** Estrogen deprivation reduces leiomyoma volume by approximately 40 to 60 percent over 3 to 6 months, facilitating subsequent surgical excision with reduced blood loss and smaller incisions [17].

**Growth plates:** In children with central precocious puberty, suppression of sex steroids decelerates skeletal maturation (bone age advancement) and linear growth velocity, preserving adult height potential [11, 12].

**Bone:** Estrogen deprivation accelerates osteoclast-mediated bone resorption, producing measurable bone mineral density loss (the principal safety limitation of treatment duration) [14, 15].

# 5. Pharmacokinetics and Routes of Administration

## 5.1 Absorption

Nafarelin is administered exclusively by the intranasal route in clinical practice. After intranasal administration of 200 or 400 micrograms, the compound is rapidly absorbed through the nasal mucosa with peak serum concentrations achieved between 10 and 40 minutes [13, 19]. Maximum serum concentrations after a 400 microgram intranasal dose are approximately 1.1 to 1.7 ng/mL in adult women.

Absolute bioavailability by the intranasal route is 2.8 percent (range 1.2 to 5.6 percent), as determined by comparison with subcutaneous injection pharmacokinetics [13]. The low bioavailability reflects the limited fraction of the administered peptide that traverses the nasal epithelium intact before mucociliary clearance and local peptidase degradation. Despite the low absolute bioavailability, the delivered systemic fraction is pharmacologically sufficient for complete pituitary desensitization at the recommended twice-daily dosing regimen, reflecting the approximately 200-fold potency advantage over native GnRH.

Nasal congestion, rhinitis, and concurrent use of nasal decongestants can reduce nafarelin absorption. The prescribing information recommends that nasal decongestants should not be used within 2 hours of nafarelin dosing and that sneezing during or immediately after dosing may reduce absorption [6].

## 5.2 Distribution

Volume of distribution has not been precisely characterized for the intranasal route owing to the low bioavailability and the complexity of peptide distribution kinetics. Plasma protein binding is approximately 80 percent [13]. The compound distributes to reproductive tissues, pituitary, and other target organs. Central nervous system penetration has not been formally characterized but is expected to be minimal for a charged decapeptide of 1322 daltons molecular weight.

## 5.3 Metabolism

Nafarelin is metabolized by tissue peptidases and is not a substrate, inhibitor, or inducer of hepatic cytochrome P450 enzymes [13, 19]. Six metabolites have been identified, of which the major metabolite is the fragment Tyr-D-Nal(2)-Leu-Arg-Pro-Gly-NH<sub>2</sub> (residues 5 through 10), produced by endopeptidase cleavage at the Ser4-Tyr5 bond [19]. The metabolites have substantially lower GnRH receptor affinity than the parent compound and are not considered pharmacologically active at concentrations achieved in vivo. The peptidase-mediated metabolism eliminates the drug-drug interaction potential that characterizes compounds metabolized by cytochrome P450 enzymes.

## 5.4 Elimination

Elimination of nafarelin and its metabolites is by both renal and fecal routes: approximately 44 to 55 percent of absorbed dose is recovered in urine and 18.5 to 44.2 percent in feces [19]. The terminal elimination half-life after intranasal administration is 2.5 to 3.0 hours. After subcutaneous injection (a research route not used in clinical practice), the apparent half-life of nafarelin and its metabolites is substantially longer (approximately 85.5 hours), reflecting slow absorption from the subcutaneous depot rather than altered elimination [13].

## 5.5 Routes of administration

The registered route of administration is exclusively intranasal. The marketed formulation (Synarel) delivers 200 micrograms per metered spray actuation from a 2 mg/mL solution in a multi-dose nasal spray bottle. Clinical doses are:

- Endometriosis: 200 micrograms in one nostril in the morning and 200 micrograms in the other nostril in the evening (total 400 micrograms daily). If amenorrhea is not achieved within 2 months, dose may be increased to 400 micrograms twice daily (total 800 micrograms daily).
- Central precocious puberty: 400 micrograms in each nostril in the morning and 400 micrograms in each nostril in the evening (total 1600 micrograms daily). Dose may be increased to 1800 micrograms daily if downregulation is incomplete.

Subcutaneous injection has been used in research pharmacokinetic studies and in some assisted reproductive technology protocols but is not a registered route and does not have an approved formulation.

## 5.6 Special populations

Pediatric pharmacokinetics in children with central precocious puberty demonstrate adequate pituitary suppression at the 1600 microgram daily intranasal dose across the age range studied (2 to 9 years). Dose is not weight-adjusted; pharmacodynamic monitoring (suppression of pubertal LH response to GnRH stimulation testing) guides dose adequacy. Hepatic and renal impairment have not been formally studied but are not expected to substantially alter pharmacokinetics given the peptidase-mediated metabolism and mixed elimination.

## 6. Preclinical Pharmacology

### 6.1 In vitro pharmacology

Nafarelin demonstrates approximately 200-fold greater potency than native GnRH in stimulating LH release from dispersed rat anterior pituitary cells and in binding to the GnRH receptor in pituitary membrane preparations [3, 16]. The enhanced potency derives from both the higher receptor affinity (lower  $K_i$ ) and the slower dissociation kinetics (longer receptor occupancy time) conferred by the D-Nal(2) substitution. In competitive binding assays against [ $^{125}$ I]-GnRH in rat pituitary membranes, nafarelin demonstrates a  $K_i$  in the low picomolar to subnanomolar range [3].

### 6.2 In vivo pharmacology

In ovariectomized rats primed with estrogen and progesterone, subcutaneous nafarelin produces dose-dependent LH release with an ED<sub>50</sub> approximately 200-fold lower than native GnRH [16]. Chronic administration (daily subcutaneous or continuous infusion) in intact female rats produces the expected biphasic response: initial stimulation followed within 7 to 14 days by suppression of estrous cyclicity, reduction in uterine weight, and suppression of ovarian follicular development.

In cynomolgus monkeys, chronic intranasal nafarelin produces suppression of menstrual cyclicity and reduction of estradiol to postmenopausal levels, with full reversibility on cessation [16]. The monkey model was used to establish proof of concept for the intranasal delivery route before human Phase 1 studies.

### 6.3 Reproductive toxicology

Standard reproductive toxicology studies in rats and rabbits at multiples of the human dose (based on body surface area) demonstrated the expected pharmacological effects of gonadal suppression (impaired fertility, reduced litter size) but did not demonstrate teratogenicity at doses up to 600 micrograms/kg/day in rats and 90

micrograms/kg/day in rabbits [6]. The compound is classified as FDA Pregnancy Category X: contraindicated in pregnancy because the pharmacological effect of gonadal steroid suppression can produce fetal harm.

## 6.4 Carcinogenicity

Two-year carcinogenicity studies in rats at subcutaneous doses of 2, 10, and 50 micrograms/kg/day showed no compound-related neoplastic findings in males. In females, the highest dose (50 micrograms/kg/day, approximately 14 times the maximum human intranasal dose on a microgram/kg basis) was associated with an increased incidence of pituitary adenomas, consistent with the known consequence of sustained GnRH receptor stimulation on gonadotrope proliferation in rodents [6]. This finding is considered species-specific and related to the sustained pharmacological stimulus rather than to genotoxicity.

# 7. Clinical Evidence Base

## 7.1 Endometriosis

The pivotal clinical evidence for nafarelin in endometriosis derives from two large randomized controlled trials:

**Henzl et al. (1988), New England Journal of Medicine:** A randomized, double-blind, double-dummy, danazol-controlled trial in 213 women with laparoscopically confirmed endometriosis [9]. Patients received nafarelin 400 micrograms/day intranasal, nafarelin 800 micrograms/day intranasal, or danazol 800 mg/day oral for 6 months. Mean American Fertility Society laparoscopic scores decreased from 21.9 to 12.6 (nafarelin 800 micrograms), from 20.4 to 11.7 (nafarelin 400 micrograms), and from 18.4 to 10.5 (danazol); all within-group reductions were significant at  $P$  less than 0.0001, with no significant differences between groups. The proportion of women with severe symptoms decreased from approximately 40 percent to 5 to 10 percent. Nafarelin 400 micrograms daily was determined to be the optimal dose (equivalent efficacy to 800 micrograms with fewer adverse events).

**Nafarelin European Endometriosis Trial (NEET, 1992):** A large-scale danazol-controlled multicenter trial in 247 women confirmed the efficacy findings of the Henzl study [10]. Nafarelin and danazol produced equivalent reductions in laparoscopic disease scores and symptom severity. The lipid profile was significantly more favorable with nafarelin (no change in HDL and LDL cholesterol) compared with danazol (decreased HDL, increased LDL). Hot flashes were more common with nafarelin; androgenic adverse events (weight gain, acne, hirsutism, voice changes) were more common with danazol.

At the end of treatment, approximately 60 percent of patients receiving nafarelin 400 micrograms daily were symptom-free, 32 percent had mild symptoms, 7 percent had moderate symptoms, and 1 percent had severe symptoms [6]. Nafarelin induced amenorrhea in approximately 65 percent, 80 percent, and 90 percent of patients by days 60, 90, and 120, respectively.

## 7.2 Central precocious puberty

Nafarelin 1600 micrograms daily by intranasal spray produces sustained suppression of pubertal LH and FSH, sex steroids (estradiol or testosterone), secondary sexual development, and skeletal maturation in children with central precocious puberty [11, 12]. Clinical effects include:

- Arrest or regression of breast development in girls and genital development in boys
- Deceleration of linear growth velocity to prepubertal rates
- Deceleration of skeletal maturation (bone age advancement)
- Suppression of GnRH-stimulated LH response to prepubertal patterns

Reversal of suppressive effects was demonstrated in all children for whom one-year post-treatment follow-up is available (n=69): return of menses in girls, return of pubertal gonadotropin and sex steroid levels, advancement of secondary sexual development, and resumption of normal growth velocity [12]. Adult height outcomes in treated cohorts demonstrate preservation of predicted adult height compared with untreated historical controls.

## 7.3 Assisted reproductive technology

Nafarelin is widely used for pituitary downregulation prior to controlled ovarian hyperstimulation in in vitro fertilization (IVF) cycles [18, 20]. The long protocol involves nafarelin 200 to 400 micrograms twice daily beginning in the mid-luteal phase of the preceding cycle, with documentation of pituitary suppression (estradiol less than 50 pg/mL, thin endometrium on ultrasound) before initiating gonadotropin stimulation. Meta-analytic data demonstrate that nafarelin produces equivalent clinical pregnancy rates to leuprolide and other GnRH agonists in IVF protocols, with no significant differences in mean duration to suppression, total gonadotropin dosage, number of oocytes retrieved, or clinical pregnancy rate [20]. The operational advantage of nafarelin in this application is the non-injectable self-administration route.

## 7.4 Uterine leiomyomas

GnRH agonists including nafarelin are used preoperatively to reduce uterine leiomyoma volume prior to myomectomy or hysterectomy [17]. Nafarelin produces approximately 40 to 60 percent reduction in fibroid volume over 3 to 6 months of treatment. Preoperative GnRH agonist therapy improves hemoglobin concentration, reduces intraoperative blood loss, increases the likelihood of vaginal rather than abdominal hysterectomy, and reduces the rate of vertical incisions during laparotomy. Bone mineral density declined at spinal and femoral sites similarly in 3-month and 6-month treatment groups, with partial but incomplete return to baseline levels after 12 to 15 months of follow-up [14]. The compound is not registered for this indication but its use is supported by multiple randomized controlled trials and Cochrane systematic reviews.

## 7.5 Other investigated applications

Nafarelin has been studied in additional clinical contexts including: premenstrual syndrome (estrogen deprivation reduces cyclical symptom severity); breast cancer adjuvant endocrine therapy (ovarian suppression in premenopausal women as an alternative to surgical oophorectomy); prostate cancer (testosterone suppression, though other GnRH agonists with depot formulations are preferred for this indication); and endometrial thinning prior to hysteroscopic surgery. None of these additional applications has produced a registered indication for nafarelin specifically, though the class pharmacology is well established for several of them.

## 8. Sourcing and Quality Verification

Pharmaceutical-grade nafarelin acetate (Synarel brand or licensed generic) is the highest quality source for research applications where regulatory equivalence to clinical material is operationally important. The pharmaceutical-grade material is supplied as a 2 mg/mL intranasal solution in multi-dose spray bottles delivering 200 micrograms per actuation.

Research-grade nafarelin acetate is supplied by multiple peptide and pharmaceutical research suppliers (Tocris Bioscience, R&D Systems, Cayman Chemical, MedChemExpress, GlpBio, Sigma-Aldrich, Bachem, others) at greater than 95 to 98 percent purity by HPLC. Supply is in milligram quantities as the acetate salt. Pricing is moderate to high for a synthetic decapeptide, reflecting the solid-phase synthesis and HPLC purification costs.

Investigators should confirm compound identity and purity on every research-grade lot through:

- Reversed-phase high-performance liquid chromatography area-percent purity, ideally greater than 95 percent
- Mass spectrometry confirmation of molecular weight (expected  $[M+H]^+$  at  $m/z$  1323.64 for the free base)
- Amino acid analysis confirming correct stoichiometry of all 10 residues including D-Nal(2)
- Peptide content determination (accounting for acetate, water, and counterion content)
- Endotoxin testing (limulus amebocyte lysate assay) if the material is intended for in vivo or cell culture applications
- Chiral amino acid analysis confirming D-configuration at position 6

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade GnRH agonist peptide market is well established; the principal quality concern is peptide content (typical peptide content of lyophilized research-grade material is 70 to 85 percent by mass, with the remainder being water, acetate counterion, and residual trifluoroacetic acid from purification).

## 9. Reconstitution and Handling

Nafarelin acetate is supplied as a lyophilized white powder (research-grade) or as a ready-to-use aqueous nasal spray solution (pharmaceutical-grade). For research applications, reconstitution of the lyophilized material follows standard peptide handling practices.

**Reconstitution for in vitro studies:** Dissolve in sterile water, phosphate-buffered saline, or dimethyl sulfoxide at concentrations of 1 to 10 mg/mL for stock solutions. The compound is freely soluble in aqueous media. Prepare aliquots for single use and store at minus 20 degrees Celsius or below. Avoid repeated freeze-thaw cycles (stable to at least 3 cycles without measurable potency loss by HPLC, but single-use aliquoting is preferred).

**Reconstitution for in vivo studies:** Dissolve in bacteriostatic water for injection, normal saline, or phosphate-buffered saline for subcutaneous or intraperitoneal administration. Filter-sterilize through 0.22 micrometer membranes. For intranasal administration in animal studies, dissolve in normal saline at appropriate concentration for the delivery volume.

**Storage conditions:** Lyophilized powder is stable at minus 20 degrees Celsius for at least 2 years when stored under desiccation. Reconstituted solutions in aqueous media should be used within 14 days at 2 to 8 degrees Celsius or within 3 months at minus 20 degrees Celsius. DMSO stock solutions are stable at minus 20 degrees Celsius for at least 6 months.

**Pharmaceutical-grade nasal spray:** Store at room temperature (20 to 25 degrees Celsius). The bottle provides approximately 60 sprays (30 days of treatment at the 400 microgram daily endometriosis dose). Protect from light. Do not freeze. Discard 30 days after first use.

**Handling precautions:** Nafarelin is a potent GnRH agonist. Personnel handling concentrated solutions should use appropriate personal protective equipment. The compound is not classified as cytotoxic or genotoxic; the primary handling concern is inadvertent pharmacological exposure through nasal inhalation or mucosal contact.

## 10. Stack Interactions and Combinations

Nafarelin has minimal cytochrome P450-mediated drug interaction potential owing to its metabolism by tissue peptidases rather than hepatic microsomal enzymes [13]. The principal interaction considerations are pharmacodynamic rather than pharmacokinetic:

**Nasal decongestants:** Concurrent use of nasal decongestant sprays (oxymetazoline, xylometazoline, phenylephrine nasal) may alter nafarelin absorption if administered within 2 hours of nafarelin dosing. The prescribing information recommends separation by at least 2 hours [6].

**Hormonal contraceptives and hormone replacement:** Exogenous estrogens, progestins, and combined hormonal contraceptives counteract the pharmacological hypoestrogenism produced by nafarelin and should be discontinued before treatment initiation. Low-dose add-back therapy (norethindrone acetate 5 mg daily, or tibolone 2.5 mg daily) is the exception: this is used deliberately to mitigate bone loss and vasomotor symptoms during extended nafarelin treatment without compromising efficacy on endometriosis or fibroids [21].

**Other GnRH agonists or antagonists:** Concurrent use with another GnRH agonist (leuprolide, goserelin, triptorelin) is pharmacologically redundant. Concurrent use with a GnRH antagonist (cetorelix, ganirelix, degarelix) produces pharmacological antagonism at the receptor level and is contraindicated except in specific assisted reproductive technology protocols where sequential use is intentional.

**Gonadotropins (FSH, hMG, LH):** In assisted reproductive technology protocols, nafarelin-induced pituitary suppression eliminates endogenous gonadotropin secretion, and exogenous gonadotropin administration (recombinant FSH, human menopausal gonadotropin) is then used to drive controlled ovarian hyperstimulation. This is the intended pharmacological combination in IVF long protocols [18, 20].

**Anticoagulants:** No characterized pharmacokinetic interaction. The intranasal route and peptidase metabolism eliminate hepatic interaction potential.

**Calcium and vitamin D:** Supplementation with calcium (1000 to 1500 mg daily) and vitamin D (400 to 800 IU daily) during nafarelin therapy may partially mitigate the bone mineral density loss associated with hypoestrogenism [15]. The Dawood et al. study suggested that recovery of bone mass after treatment cessation was more complete in subjects with higher dietary calcium intakes.

**Corticosteroids (intranasal):** Concurrent intranasal corticosteroids (fluticasone, mometasone, budesonide) for allergic rhinitis may alter nafarelin nasal absorption through effects on mucosal inflammation and permeability. Clinical significance is uncertain; monitoring of treatment response is appropriate.

# 11. Adverse Events and Safety

## 11.1 Common adverse events

The principal adverse events of nafarelin are the predictable pharmacological consequences of estrogen deprivation (hypoestrogenism) and local nasal effects:

### **Hypoestrogenic effects (endometriosis, adult women):**

- Hot flashes: reported in up to 90 percent of patients, the most common adverse event
- Decreased libido: approximately 20 to 25 percent
- Vaginal dryness: approximately 15 to 20 percent
- Emotional lability and mood changes: approximately 15 percent
- Headache: approximately 10 to 15 percent
- Insomnia: approximately 5 to 10 percent
- Myalgia and arthralgia: approximately 5 to 10 percent
- Acne and seborrhea: approximately 10 to 15 percent

### **Local nasal effects:**

- Nasal irritation: approximately 10 percent
- Rhinitis: approximately 5 percent
- Epistaxis: rare

These adverse-event rates are consistent with the class effects of GnRH agonist therapy and are similar in magnitude and distribution to those reported for leuprolide, goserelin, and other agents in the class [22].

## 11.2 Bone mineral density

The most clinically significant adverse effect of nafarelin is reduction in bone mineral density during treatment. The induced hypoestrogenism accelerates osteoclast-mediated bone resorption:

- Vertebral bone mineral density decreases by approximately 3 to 6 percent over 6 months of treatment [14, 15]
- Femoral bone mineral density decreases by approximately 2 to 4 percent over 6 months
- Recovery after treatment cessation is partial but incomplete: bone density returns toward but does not fully reach pretreatment values at 12 to 15 months of follow-up
- Recovery is more complete in patients with adequate calcium intake and in younger patients
- Retreatment with a second 6-month course produces additional bone loss

The bone density concern limits the approved treatment duration to 6 months for the endometriosis indication without add-back therapy. Addition of norethindrone acetate 5 mg daily as add-back therapy preserves bone density during treatment and permits extended treatment courses [21].

### 11.3 Initial flare effects

The initial stimulatory flare (days 1 to 14 of treatment) may produce transient worsening of estrogen-dependent symptoms including increased pelvic pain, breakthrough bleeding, and breast tenderness. The flare is self-limiting and resolves as pituitary desensitization occurs.

### 11.4 Pediatric considerations

In children with central precocious puberty, the adverse-event profile differs from adults:

- Hot flashes are less frequently reported than in adults
- Emotional lability and behavioral changes are reported
- Body odor and acne (preexisting signs of precocious puberty) resolve with treatment
- Pseudotumor cerebri (idiopathic intracranial hypertension) has been reported rarely in children receiving GnRH agonists as a class [23]
- Bone density is monitored but the concern is less acute than in adults because the treatment period typically spans active skeletal growth

## 11.5 Pregnancy

Nafarelin is contraindicated in pregnancy (FDA Pregnancy Category X). The pharmacological suppression of gonadal steroids can produce fetal harm. Patients must use non-hormonal contraception during treatment. A pregnancy test should be obtained before treatment initiation [6].

## 11.6 Cardiovascular and metabolic

Unlike danazol, nafarelin does not produce unfavorable changes in lipid profiles (no decrease in HDL cholesterol, no increase in LDL cholesterol) [9, 10]. Glucose metabolism and body weight are not materially affected at registered doses. Cardiovascular adverse events are not a feature of the GnRH agonist class at the treatment durations used for endometriosis and precocious puberty; longer-term effects on cardiovascular risk from sustained hypoestrogenism are a theoretical concern but have not been characterized for nafarelin specifically.

## 12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five gonadotropin-releasing hormone agonist alternatives against nafarelin, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal GnRH agonists with established clinical applications in endometriosis, central precocious puberty, and reproductive endocrinology.

### 12.1 Leuprolide (Lupron, Eligard)

**Mechanism:** Synthetic nonapeptide GnRH superagonist with D-leucine at position 6 and ethylamide at the C-terminus. Mechanism identical to nafarelin: pituitary GnRH receptor desensitization and gonadotropin suppression.

**Development trajectory:** Abbott Laboratories (subsequently AbbVie and TAP Pharmaceutical Products). FDA-approved 1985 for prostate cancer, subsequently approved for endometriosis (1990), central precocious puberty (1993), uterine leiomyomas, and breast cancer. The most widely prescribed GnRH agonist globally.

**Novelty:** Low. The D-Leu6 substitution is the simplest of the position-6 modifications and was among the earliest characterized. Leuprolide preceded nafarelin to market by 5 years.

**Effect size:** Equivalent to nafarelin in endometriosis symptom relief and laparoscopic score reduction in head-to-head comparisons. Equivalent gonadotropin and sex steroid suppression in central precocious puberty and IVF downregulation protocols [22, 24].

**Promising potential:** High. The compound dominates the market through its depot formulations (1-month, 3-month, 4-month, and 6-month intramuscular or subcutaneous depot injections) that provide sustained drug delivery without daily administration. This formulation advantage is the principal competitive differentiation over nafarelin.

**Side-effect profile:** Class-equivalent hypoestrogenic adverse events. Injection site reactions (pain, nodules, sterile abscess) are a route-specific adverse event not shared with nafarelin. Bone density loss equivalent in magnitude and time course to nafarelin [22].

**Overall validation:** Very high. The most extensively studied GnRH agonist with the broadest regulatory approval history across multiple indications.

**Comparison to nafarelin:** Leuprolide and nafarelin produce equivalent pharmacological effects through identical mechanisms. The differentiating factor is route and formulation: leuprolide is available in depot injections providing 1 to 6 months of sustained delivery from a single administration, while nafarelin requires twice-daily intranasal dosing. The depot advantage of leuprolide ensures superior adherence in settings where daily compliance is uncertain. The nafarelin advantage is non-injectable self-administration, avoiding injection site reactions and eliminating the need for healthcare provider visits for administration.

## 12.2 Goserelin (Zoladex)

**Mechanism:** Synthetic decapeptide GnRH superagonist with D-Ser(tBu) at position 6 and azaglycinamide at the C-terminus. Mechanism identical to nafarelin.

**Development trajectory:** ICI Pharmaceuticals (subsequently AstraZeneca). FDA-approved 1989 for prostate cancer, subsequently approved for breast cancer (1993) and endometriosis (1996). Available as a subcutaneous biodegradable implant (Zoladex depot) providing 1-month or 3-month sustained release.

**Novelty:** Low. Standard position-6 D-amino acid substitution with an additional C-terminal modification.

**Effect size:** Equivalent to nafarelin and leuprolide in gonadotropin suppression and clinical endpoints across shared indications. In prostate cancer, goserelin has demonstrated better maintenance of castrate testosterone levels compared with leuprolide in some comparative analyses [25].

**Promising potential:** Moderate to high. Established product with stable market position. The implant delivery system is well accepted in oncology (prostate cancer, breast cancer) where long-term treatment is standard.

**Side-effect profile:** Class-equivalent hypoestrogenic effects. The subcutaneous implant produces local reactions (injection site pain, bruising) and rarely implant migration. No nasal adverse events.

**Overall validation:** High. Extensive clinical evidence base across prostate cancer, breast cancer, and endometriosis.

**Comparison to nafarelin:** Goserelin offers the depot advantage (1-month or 3-month implant versus twice-daily nasal spray) with the corresponding adherence benefit. Nafarelin offers non-invasive self-administration. The clinical choice typically reflects the indication: goserelin is preferred in oncology settings requiring assured compliance; nafarelin is an option in endometriosis where patient autonomy and avoidance of injection are valued.

## 12.3 Triptorelin (Decapeptyl, Trelstar)

**Mechanism:** Synthetic decapeptide GnRH superagonist with D-tryptophan at position 6. Mechanism identical to nafarelin.

**Development trajectory:** Debiopharm/Ipsen. Approved in multiple jurisdictions for prostate cancer, endometriosis, central precocious puberty, uterine fibroids, and assisted reproduction. Available as intramuscular depot injections (1-month, 3-month, and 6-month formulations).

**Novelty:** Low. Standard position-6 D-amino acid substitution.

**Effect size:** Equivalent to other GnRH agonists across shared indications. A Cochrane review found no significant differences between triptorelin and leuprolide or goserelin in prostate cancer endpoints [25].

**Promising potential:** Moderate to high. Established product with broad approval across multiple indications and formulations.

**Side-effect profile:** Class-equivalent. Injection site reactions with depot formulations. Rare anaphylactic reactions reported.

**Overall validation:** High. Extensive European and global clinical evidence base.

**Comparison to nafarelin:** Functionally equivalent mechanism and efficacy. Triptorelin offers depot formulation convenience; nafarelin offers non-injectable administration. In assisted reproductive technology, both compounds are used for

pituitary downregulation with equivalent clinical outcomes [20].

## 12.4 Buserelin (Suprefact)

**Mechanism:** Synthetic nonapeptide GnRH superagonist with D-Ser(tBu) at position 6 and ethylamide at the C-terminus. Mechanism identical to nafarelin.

**Development trajectory:** Hoechst (subsequently Sanofi-Aventis). First GnRH agonist approved clinically (1984, Europe). Available as intranasal spray, subcutaneous injection, and depot implant in various jurisdictions. Not FDA-approved in the United States.

**Novelty:** Low. Among the earliest GnRH superagonists developed; the position-6 D-Ser(tBu) substitution is standard.

**Effect size:** Equivalent to other GnRH agonists across shared indications. Intranasal bioavailability is approximately 3 percent, similar to nafarelin [26].

**Promising potential:** Low to moderate. The compound is well established but is principally available in non-US markets. Not actively developed for new indications.

**Side-effect profile:** Class-equivalent hypoestrogenic effects. Intranasal formulation produces similar local nasal effects to nafarelin.

**Overall validation:** Moderate to high. Long clinical history (approved since 1984) with extensive European evidence base.

**Comparison to nafarelin:** Buserelin is the most structurally and pharmacologically similar comparator to nafarelin: both are intranasal GnRH agonists with low bioavailability (approximately 3 percent) compensated by high receptor potency. Nafarelin has approximately 2-fold greater receptor affinity than buserelin, permitting lower microgram doses. The choice between them is principally geographic: nafarelin is the US-market intranasal GnRH agonist; buserelin is the European and Canadian equivalent.

## 12.5 Histrelin (Supprelin LA, Vantas)

**Mechanism:** Synthetic nonapeptide GnRH superagonist with D-His(benzyl) at position 6 and ethylamide at the C-terminus. Mechanism identical to nafarelin.

**Development trajectory:** Roberts Pharmaceutical (subsequently Endo Pharmaceuticals). FDA-approved as Supprelin LA (2007) for central precocious puberty and as Vantas (2005) for prostate cancer. Distinctive delivery system: a subcutaneous hydrogel implant providing 12 months of sustained drug release from a single implantation.

**Novelty:** Moderate. The compound itself is not novel (identified in the 1970s) but the 12-month subcutaneous implant delivery system is unique among GnRH agonists and represents a genuine formulation innovation.

**Effect size:** Equivalent to other GnRH agonists in gonadotropin and sex steroid suppression. The 12-month implant provides the most sustained and consistent drug delivery of any GnRH agonist formulation, with documented maintenance of suppression throughout the 12-month interval in greater than 95 percent of patients [27].

**Promising potential:** Moderate. The 12-month implant is particularly valuable in central precocious puberty (avoiding monthly or 3-monthly injections in children) and in prostate cancer (annual implant replacement). Limited by the minor surgical procedure required for implant insertion and removal.

**Side-effect profile:** Class-equivalent hypoestrogenic effects. Implant site reactions (bruising, pain, encapsulation) are specific to this delivery system. Implant breakage on removal has been reported rarely.

**Overall validation:** Moderate to high. Established in central precocious puberty and prostate cancer; not approved for endometriosis.

**Comparison to nafarelin:** Histrelin and nafarelin share the central precocious puberty indication but differ fundamentally in administration: histrelin provides 12 months of suppression from a single implant, while nafarelin requires twice-daily intranasal dosing. In pediatric CPP, the implant offers superior adherence and eliminates the compliance burden on children and caregivers. Nafarelin offers the advantage of non-invasive administration and immediate reversibility (suppression ceases within days of stopping nasal spray, versus requiring implant removal for histrelin). The clinical choice reflects the balance between adherence assurance (favoring histrelin) and flexibility/reversibility (favoring nafarelin).

## 12.6 Comparator summary

The five GnRH agonist comparators are mechanistically identical to nafarelin and produce equivalent pharmacological effects and clinical efficacy across all shared indications. The competitive differentiation is driven entirely by formulation and route of administration rather than by pharmacological differences. **Leuprolide** is the market leader through its depot injection formulations (1 to 6 months) and broadest regulatory approvals. **Goserelin** offers a subcutaneous implant with strong oncology positioning. **Triptorelin** provides equivalent depot options with a strong European evidence base. **Buserelin** is the most directly comparable compound (intranasal route, similar bioavailability) with geographic differentiation. **Histrelin** offers the unique 12-month implant delivery with particular value in pediatric CPP and prostate cancer.

Nafarelin occupies a unique position in this comparator landscape as the only FDA-approved exclusively intranasal GnRH agonist. This positioning confers the advantages of non-injectable self-administration, immediate dose adjustability, rapid reversibility on cessation, patient autonomy, and avoidance of injection site reactions. The corresponding disadvantage is the requirement for twice-daily compliance, which is a material limitation in populations where adherence is uncertain (particularly children with CPP, where the histrelin implant offers a compelling alternative). For the endometriosis indication in adult women, where treatment duration is limited to 6 months and patient motivation is typically high, the intranasal route is well suited and compliance is generally adequate.

The research-clinical positioning of nafarelin is that of a compound with well-established efficacy equivalent to all comparators, a unique and patient-friendly delivery route, an extensive safety database, and a clear limitation (twice-daily compliance requirement, treatment duration limited by bone density concerns). Investigators selecting among GnRH agonists for research applications should consider the specific requirements of their protocol: for studies requiring assured compliance and sustained suppression, depot formulations (leuprolide, goserelin, triptorelin) are preferred; for studies requiring dose flexibility, rapid reversibility, or avoidance of injection, nafarelin is the appropriate choice.

## 13. References

1. Nestor JJ Jr, Ho TL, Simpson RA, et al. Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone. *J Med Chem.* 1982;25(8):960-964.
2. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. *Endocr Rev.* 1986;7(1):44-66.
3. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. *Annu Rev Med.* 1994;45:391-405.
4. Barlos K, Gatos D. 9-Fluorenylmethyloxycarbonyl/tBu amino acids and peptides: chemistry and applications in peptide synthesis. *Biopolymers.* 1999;51(4):266-278.
5. United States Pharmacopeia. Monograph: Nafarelin Acetate. USP-NF.
6. Synarel (nafarelin acetate) nasal solution prescribing information. Pfizer Laboratories. 2022.
7. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. *N Engl J Med.* 1991;324(2):93-103.
8. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. *Endocr Rev.* 2004;25(2):235-275.
9. Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. *N Engl J Med.* 1988;318(8):485-489.
10. The Nafarelin European Endometriosis Trial Group (NEET). Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. *Fertil Steril.* 1992;57(3):514-522.
11. Pescovitz OH, Comite F, Cassorla F, et al. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. *J Clin Endocrinol Metab.* 1984;58(5):857-861.

12. Hopwood NJ, Kelch RP, Hale PM, et al. The onset of human puberty: biological and clinical significance of concentrations of gonadotropins and sex steroids during the peripubertal period and their impact on the use of gonadotropin-releasing hormone agonists. *J Pediatr.* 1990;117(4 Pt 2):S47-S51.
13. Chrisp P, Goa KL. Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. *Drugs.* 1990;39(4):523-551.
14. Dawood MY, Ramos J, Khan-Dawood FS. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. *Fertil Steril.* 1995;63(6):1177-1183.
15. Fogelman I. Gonadotropin-releasing hormone agonists and the skeleton. *Fertil Steril.* 1992;57(4):715-724.
16. Vickery BH, Nestor JJ Jr. Luteinizing hormone-releasing hormone analogs: development and mechanism of action. *Semin Reprod Endocrinol.* 1987;5(4):353-370.
17. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. *Cochrane Database Syst Rev.* 2001;(2):CD000547.
18. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. *Fertil Steril.* 1992;58(5):888-896.
19. Nerenberg C, Gothel S, Groom S. Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. *Drug Metab Dispos.* 1989;17(6):650-656.
20. Tan SL, Kingsland C, Campbell S, et al. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. *Fertil Steril.* 1992;57(4):810-814.
21. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. *Obstet Gynecol.* 2002;99(5 Pt 1):709-719.

22. Dlugi AM, Miller JD, Knittle J, Lupron Study Group. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. *Fertil Steril*. 1990;54(3):419-427.
23. US Food and Drug Administration. FDA Drug Safety Communication: Update on GnRH agonists - new cases of pseudotumor cerebri. 2014.
24. Shaw RW. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. *Fertil Steril*. 1992;58(2):265-272.
25. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int*. 2008;102(11):1531-1538.
26. Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. *N Engl J Med*. 1985;312(16):1023-1028.
27. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. *J Clin Endocrinol Metab*. 2007;92(5):1697-1704.

---

*This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Nafarelin acetate (Synarel) is approved by the United States Food and Drug Administration for the management of endometriosis and for the treatment of central precocious puberty. All other applications discussed in this monograph are investigational or off-label. Investigators should consult their local regulatory authority and institutional review board before any human research application. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.*